BioCentury | Dec 4, 2018
Distillery Techniques

Assays and screens; drug platforms

TECHNOLOGY: Cellular assays; cell therapies A sequencing-based method of identifying neoantigen-specific TCRs could be used to develop personalized T cell therapies for cancer. The method involves six steps: using in vitro transcription and translation techniques...
BioCentury | Jan 26, 2012
Distillery Techniques

Technology: Drug platforms

Drug platforms Chimpanzee adenovirus vectors for vaccine development Human, primate and mouse studies suggest chimpanzee adenovirus vectors could be used in vaccines. In nonhuman primates, a replication-deficient chimpanzee adenovirus serotype 3 (ChAd3) vector encoding an...
BioCentury | Nov 8, 2010
Clinical News

GI-5005: Additional Phase IIb data

...markets Pegasys and Copegus. GlobeImmune Inc. , Louisville, Colo. Product: GI-5005 Business: Infectious Molecular target: HCV antigens...
BioCentury | Apr 26, 2010
Clinical News

GI-5005: Additional Phase IIb data

...markets Pegasys and Copegus. GlobeImmune Inc. , Louisville, Colo. Product: GI-5005 Business: Infectious Molecular target: HCV antigens...
BioCentury | Apr 19, 2010
Clinical News

GI-5005: Additional Phase IIb data

...markets Pegasys and Copegus. GlobeImmune Inc. , Louisville, Colo. Product: GI-5005 Business: Infectious Molecular target: HCV antigens...
BioCentury | Nov 9, 2009
Clinical News

GI-5005: Additional Phase IIb data

...SIX:ROG; OTCQX:RHHBY, Basel, Switzerland). GlobeImmune Inc. , Louisville, Colo. Product: GI-5005 Business: Infectious Molecular target: HCV antigens...
BioCentury | Jun 15, 2009
Clinical News

PRO 206: Development discontinued

...next year. Progenics Pharmaceuticals Inc. (NASDAQ:PGNX), Tarrytown, N.Y. Product: PRO 206 Business: Infectious Molecular target: HCV antigens...
BioCentury | May 4, 2009
Clinical News

GI-5005: Interim Phase II data

...BioCentury, Sept. 29, 2008). GlobeImmune Inc. , Louisville, Colo. Product: GI-5005 Business: Infectious Molecular target: HCV antigens...
BioCentury | Sep 29, 2008
Clinical News

GI-5005: Interim Phase II data

...vs -0.88 log10/mo; p=0.02). GlobeImmune Inc. , Louisville, Colo. Product: GI-5005 Business: Infectious Molecular target: HCV antigens...
BioCentury | May 26, 2008
Clinical News

GI-5005: Completed Phase II enrollment

...or without subcutaneous GI-5005. GlobeImmune Inc. , Louisville, Colo. Product: GI-5005 Business: Infectious Molecular target: HCV antigens...
Items per page:
1 - 10 of 22